PTCT

#1073
PTC Therapeutics, Inc.
68.19
+1.90%
Secteur:
Base:
Devise de Profit:
Range quotidien
68.19
68.19
Range Annuel
35.95
87.50
Changement quotidien
+1.90%
Changement Mensuel
-11.29%
Evolution sur 6 mois
+34.82%
Changement Annuel
+50.03%
Clôture Précédente
66.92
Open
68.19
Bid
Ask
Low
68.19
High
68.19
Volume
121
Open full chart

Financials

Overview Relevé Statistics Dividends
Quarterly Annual
  • Market Capitalization 5.42 B
  • Employee 939
  • Founded 1998
  • CEO Matthew B. Klein
  • Website www.ptcbio.com
  • Headquarter Delaware, United States
  • FIGI BBG000QT15P7
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
9.76
Price to sales ratio
3.88
Dividends per share
—
Dividend yield %
—

PTC Therapeutics Inc

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.

Nouvelles